Top Markets
Coin of the day
Septerna Inc Septerna Inc

Septerna Inc

SEPN
株式のランク #6846
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops... Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
株価
$40.61
最終同期: 2026-08-27
時価総額
$1.83B
変化(1日)
0.89%
変化(1年)
230.70%
US
取引 Septerna Inc (SEPN)

カテゴリー

Septerna Inc(SEPN)の配当利回りの履歴
Septerna Inc(銘柄コード: SEPN)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Septerna Inc(SEPN)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)